25 nov: Matas mærker stigende interesse blandt kunderne på Black Friday -..
25 nov: Shipping: Baltic Dry-indekset falder 1,7 pct. til 1181 point
25-11-2016 14:07:32

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
11:55 - 
Aktier/middag: Bavarian Nordic topper i rødt C25
09:13 - 
Aktier/åbning: Genmab topper positivt C25 efter flere n..
08:21 - 
Aktier/tendens: Genmab kan tage fokus i forventet nervø..
Relateret debat
17:23 - 
Rigtig god dag hvor udlandet sugede det store udsalg fr..
17:10 - 
Lad os se om ikke ZP's ledelse har et par gode kort i æ..
17:09 - 
Interssant handelsmønster i dag. 160.500 stk handlet me..

Company announcement - No. 47 / 2016

 

 

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 25 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 57,913 divided into 57,913 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under three of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share for 35,851 of the new shares, DKK 50.27 per share for 17,062 of the new shares and DKK 87.45 per share for 5,000 of the new shares. The total proceeds to Zealand from the capital increase amounts to DKK 4,055,483.74.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,128,366 divided into 26,128,366 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) in the United States, and in Europe a CHMP positive opinion recommendation was given on 11 November. Suliqua(TM) is the brand name in Europe.

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

47-16_1125 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771857.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 jan
ZEAL
Godt at se at de kan hoppe direkte i fase 3 og ikke skal køre kombineret fase 2-3 studie. Det betyde..
6
19 jan
ZEAL
Published: 23:30 CET 19-01-2018 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814 ..
5
15 jan
ZEAL
I den norske udgave af Dagens Medicin er en interssant artikel (se nedenfor). Artiklen diskuterer at..
5
14:23
ZEAL
Danske Bank har en elller flere kunder der vil  købe min 25.000 stk aktier i Zealand - det kan være ..
4
21 jan
ZEAL
Sidste uge sluttede med at der efter US lukke tid kom accept fra FDA til direkte at gå i fase 3 med ..
4
15:33
ZEAL
hvem siger, at de er tilfældige. Det er vist bare noget du finder på, fordi du ikke ved hvad de lave..
3
20 jan
ZEAL
"Måske tager jeg fejl"... Nye toner fra Baronen, som ellers aldrig fejler.. Det lover godt for frem..
2
19 jan
ZEAL
Zealand Pharma får direktør for udvikling på ny chefstol09:21Zealand Pharma har styrket sin direktio..
2
17:23
ZEAL
Rigtig god dag hvor udlandet sugede det store udsalg fra Danske Bank's kunde.
1
16:04
ZEAL
Synes du markedet har taget godt imod? Øhh
1

Bavarian rider med på biotekbølge: Aktien stiger godt 5 pct.

22-01-2018 15:05:51
Bavarian Nordic er i forrygende form på børsen i København mandag eftermiddag, hvor aktien stiger med 5,3 pct. til 244,30 kr.Der er ikke umiddelbart selskabsspecifikke nyheder i markedet, der kan forklare fremgangen, men fokus er der i hvert fald til hele sektoren, efter at der er blevet annonceret to store handler i USA.Det kaster også udenlandsk interesse i retningen af Bavarian Nordic, hvor ude..

TDC danner ny digital forretningsenhed - NY

22-01-2018 13:11:01
TDC danner med virkning fra den 1. februar en ny forretningsenhed, Digital, med henblik på at styrke den digitale transformation i selskabet.Den nye enhed vil omfatte visse it- og udviklingsaktiviteter samt medarbejdere fra TDC Operations og vil samlet beskæftige over 500 ansatte inklusive tilknyttede medarbejdere fra Yousee og TDC Erhverv.- Digitals vigtigste formål er at samle de digitale ressou..

Aktier/åbning: Genmab topper positivt C25 efter flere nyheder

22-01-2018 09:13:08
Flere af de danske biotekselskaber, herunder Genmab, løfter sig fra handelsstart mandag morgen og er med til at hive det samlede eliteindeks opad.Efter nogle få minutters handler stiger eliteindekset, C25, med 0,1 pct. til 1163,87. Det sker på trods af den midlertidige nedlukning af statsapparatet i USA, som kommer som følge af foreløbigt mislykkede forhandlinger om et budgetforlig mellem Demokrat..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab får hastebehandlet Darzalex-ansøgning i USA
2
Aktier/tendens: Genmab kan tage fokus i forventet nervøs åbning
3
Aktier/åbning: Genmab topper positivt C25 efter flere nyheder
4
Aktier/middag: Bavarian Nordic topper i rødt C25
5
Genmab-konkurrent vil købe amerikansk biotekselskab for 55 milliarder

Relaterede aktiekurser

Zealand Pharma A/S 91,50 1,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. januar 2018 19:12:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180122.1 - EUROWEB2 - 2018-01-22 19:12:31 - 2018-01-22 19:12:31 - 1 - Website: OKAY